US5849719A
(en)
*
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6429199B1
(en)
*
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
ES2283012T3
(es)
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
Bacterioferritina de helicobacter pylori.
|
US20030078223A1
(en)
*
|
1996-01-30 |
2003-04-24 |
Eyal Raz |
Compositions and methods for modulating an immune response
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
BR9910643A
(pt)
*
|
1998-05-22 |
2001-10-30 |
Loeb Health Res Inst At The Ot |
Processos e produtos para a indução de imunidadede mucosa
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
JP4620251B2
(ja)
|
1998-08-10 |
2011-01-26 |
アンチジェニックス・インコーポレイテッド |
Cpgおよびサポニンアジュバントの組成物並びにその方法
|
WO2000048630A1
(en)
|
1999-02-17 |
2000-08-24 |
Csl Limited |
Immunogenic complexes and methods relating thereto
|
JP4812942B2
(ja)
*
|
1999-02-26 |
2011-11-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
CGモチーフを含むオリゴヌクレオチドを用いるNeisseria抗原殺菌活性の増強
|
PL203951B1
(pl)
*
|
1999-04-19 |
2009-11-30 |
Smithkline Beecham Biolog |
Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
AU5821000A
(en)
*
|
1999-06-29 |
2001-01-31 |
Smithkline Beecham Biologicals (Sa) |
Vaccine
|
US20050002958A1
(en)
*
|
1999-06-29 |
2005-01-06 |
Smithkline Beecham Biologicals Sa |
Vaccines
|
RS50325B
(sr)
*
|
1999-09-25 |
2009-09-08 |
University Of Iowa Research Foundation, |
Imunostimulatorne nukleinske kiseline
|
US6949520B1
(en)
*
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
CA2397374A1
(en)
*
|
2000-01-13 |
2001-07-19 |
Antigenics Inc. |
Innate immunity-stimulating compositions of cpg and saponin and methods thereof
|
WO2001095935A1
(en)
*
|
2000-01-20 |
2001-12-20 |
Ottawa Health Research Institute |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
HUP0300067A3
(en)
*
|
2000-02-21 |
2010-03-29 |
Lundbeck & Co As H |
Novel method for down-regulation of amyloid
|
KR20080017471A
(ko)
*
|
2000-02-21 |
2008-02-26 |
파멕사 에이/에스 |
아밀로이드의 하향-조절을 위한 신규한 방법
|
US7129222B2
(en)
*
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
US20030129251A1
(en)
*
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
AU4791901A
(en)
*
|
2000-03-30 |
2001-10-15 |
Dendreon Corp |
Compositions and methods for dendritic cell-based immunotherapy
|
AU2001282475A1
(en)
*
|
2000-08-25 |
2002-03-04 |
Yeda Research And Development Co. Ltd. |
Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide
|
PL208755B1
(pl)
*
|
2000-10-18 |
2011-06-30 |
Glaxosmithkline Biolog Sa |
Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
|
PL211151B1
(pl)
*
|
2000-10-18 |
2012-04-30 |
Glaxosmithkline Biolog Sa |
Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
|
GB0025577D0
(en)
*
|
2000-10-18 |
2000-12-06 |
Smithkline Beecham Biolog |
Vaccine
|
EP2277894A1
(de)
|
2000-10-27 |
2011-01-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Nukleinsäure und Proteine von Gruppen A und B Streptokokken
|
US7776523B2
(en)
|
2000-12-07 |
2010-08-17 |
Novartis Vaccines And Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
WO2002053141A2
(en)
*
|
2000-12-14 |
2002-07-11 |
Coley Pharmaceutical Group, Inc. |
Inhibition of angiogenesis by nucleic acids
|
EP1347775B1
(de)
*
|
2001-01-05 |
2016-11-30 |
Valneva Austria GmbH |
Gebrauch von polykationischen substanzen als adjuvantien für impfstoffe
|
US20040081655A1
(en)
*
|
2001-01-05 |
2004-04-29 |
Karen Lingnau |
Methods and compositions comprising polycationic compounds
|
US7244438B2
(en)
|
2001-01-05 |
2007-07-17 |
Intercell Ag |
Uses for polycationic compounds
|
JP2004519453A
(ja)
*
|
2001-01-05 |
2004-07-02 |
インターツェル・アクチェンゲゼルシャフト |
ポリカチオン性化合物の用途
|
AU2002305914A1
(en)
*
|
2001-01-12 |
2002-10-21 |
Chiron Corporation |
Nucleic acid mucosal immunization
|
US7713942B2
(en)
|
2001-04-04 |
2010-05-11 |
Nordic Vaccine Technology A/S |
Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
|
US20100221284A1
(en)
*
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
SK15762003A3
(sk)
|
2001-06-29 |
2005-01-03 |
Chiron Corporation |
Kompozícia vakcíny HCV E1E2
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US20030138434A1
(en)
*
|
2001-08-13 |
2003-07-24 |
Campbell Robert L. |
Agents for enhancing the immune response
|
MY144532A
(en)
*
|
2001-08-20 |
2011-09-30 |
Lundbeck & Co As H |
Novel method for down-regulation of amyloid
|
US20030091593A1
(en)
*
|
2001-09-14 |
2003-05-15 |
Cytos Biotechnology Ag |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
DK1450856T3
(da)
|
2001-09-14 |
2010-05-31 |
Cytos Biotechnology Ag |
Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
|
GB0123580D0
(en)
*
|
2001-10-01 |
2001-11-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
KR20050048539A
(ko)
*
|
2001-10-06 |
2005-05-24 |
메리얼엘엘씨 |
CpG 제제 및 관련된 방법
|
TW200303759A
(en)
*
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
AU2006200116B2
(en)
*
|
2001-11-27 |
2009-03-19 |
Schering Corporation |
Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
|
WO2003055514A1
(en)
|
2001-12-21 |
2003-07-10 |
Antigenics Inc. |
Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
|
JP4646516B2
(ja)
|
2002-02-20 |
2011-03-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着したポリペプチド含有分子を有する微粒子
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
JP2005535308A
(ja)
|
2002-06-13 |
2005-11-24 |
カイロン コーポレイション |
Hml−2ポリペプチド発現用ベクター
|
US7807803B2
(en)
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US20040053880A1
(en)
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
CA2494911A1
(en)
|
2002-08-12 |
2004-02-19 |
Dynavax Technologies Corporation |
Immunomodulatory compositions, methods of making, and methods of use thereof
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004053104A2
(en)
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
AU2003300831A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Hawaii Biotech, Inc. |
Recombinant vaccine against flavivirus infection
|
EP2263687B1
(de)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogene zusammensetzungen enthaltend phospholipid
|
ES2562456T3
(es)
*
|
2003-03-24 |
2016-03-04 |
Valneva Austria Gmbh |
Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
ZA200507063B
(en)
|
2003-03-26 |
2007-03-28 |
Cytos Biotechnology Ag |
Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
WO2004087203A2
(en)
*
|
2003-04-02 |
2004-10-14 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
WO2004092360A2
(en)
|
2003-04-10 |
2004-10-28 |
Chiron Corporation |
The severe acute respiratory syndrome coronavirus
|
CN1798548B
(zh)
|
2003-06-02 |
2010-05-05 |
诺华疫苗和诊断公司 |
基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
EP1670507A4
(de)
*
|
2003-09-12 |
2007-10-17 |
Antigenics Inc |
Vakzine zur behandlung und prävention von herpes simplex-virusinfektion
|
GB0323968D0
(en)
*
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
GB0323965D0
(en)
*
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
ATE554106T1
(de)
|
2003-12-23 |
2012-05-15 |
Arbor Vita Corp |
Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
|
EP1550458A1
(de)
*
|
2003-12-23 |
2005-07-06 |
Vectron Therapeutics AG |
Synergisitische liposomale Adjuvantien
|
TWI235440B
(en)
*
|
2004-03-31 |
2005-07-01 |
Advanced Semiconductor Eng |
Method for making leadless semiconductor package
|
DK1742659T3
(da)
*
|
2004-04-05 |
2013-06-03 |
Zoetis P Llc |
Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger
|
GB0411411D0
(en)
*
|
2004-05-21 |
2004-06-23 |
Glaxosmithkline Biolog Sa |
Vaccines
|
US20090263470A1
(en)
|
2004-05-28 |
2009-10-22 |
Beth-Ann Coller |
Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant
|
CA2571421A1
(en)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Compounds for immunopotentiation
|
KR100958505B1
(ko)
*
|
2004-07-18 |
2010-05-17 |
씨에스엘 리미티드 |
면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
|
JP2008506683A
(ja)
*
|
2004-07-18 |
2008-03-06 |
コーリー ファーマシューティカル グループ, リミテッド |
先天免疫応答を誘導するための方法および組成物
|
DE102004038535B4
(de)
*
|
2004-08-06 |
2012-10-04 |
Universitätsklinikum Schleswig-Holstein |
Zelluläre Einschleusung von Nukleinsäurewirkstoffen
|
EP1850860A2
(de)
*
|
2005-01-13 |
2007-11-07 |
The Johns Hopkins University |
Prostatastammzellenantigenimpfstoffe und verwendungen davon
|
EP2433647A3
(de)
|
2005-01-27 |
2012-06-06 |
Children's Hospital & Research Center at Oakland |
Gna1870-basierte vesikelimpfstoffe für breitbandschutz gegen neisseria meningitidis-bedingte erkrankungen
|
WO2006123155A2
(en)
*
|
2005-05-19 |
2006-11-23 |
Glaxosmithkline Biologicals S.A. |
Vaccine composition comprising b-subunit of e. coli heat toxin and an atigen and an adjuvant
|
FR2888117B1
(fr)
*
|
2005-07-07 |
2009-10-09 |
Sanofi Pasteur Sa |
Composition vaccinale comprenant une emulsion thermoreversible
|
AR054822A1
(es)
*
|
2005-07-07 |
2007-07-18 |
Sanofi Pasteur |
Emulsion inmuno adyuvante
|
US8703095B2
(en)
*
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
WO2007015167A2
(en)
*
|
2005-08-02 |
2007-02-08 |
Novartis Vaccines And Diagnostics Srl |
Reducing interference between oil-containing adjuvants and surfactant-containing antigens
|
WO2007028985A2
(en)
*
|
2005-09-07 |
2007-03-15 |
The Secretary Of State For Defence |
Adjuvanted vaccine
|
EP1928539A1
(de)
*
|
2005-09-30 |
2008-06-11 |
Tti Ellebeau, Inc. |
Transdermale funktionalisierte mikronadel-arzneiabgabesysteme, vorrichtungen und verfahren
|
KR20080066712A
(ko)
*
|
2005-09-30 |
2008-07-16 |
티티아이 엘뷰 가부시키가이샤 |
관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
|
KR20080080087A
(ko)
*
|
2005-09-30 |
2008-09-02 |
티티아이 엘뷰 가부시키가이샤 |
신규 약학 담체를 이용한 경피 약물 전달시스템, 장치 및방법
|
ES2525518T3
(es)
*
|
2005-11-01 |
2014-12-26 |
Novartis Vaccines And Diagnostics Gmbh |
Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
CA2628424A1
(en)
*
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
PL2368572T3
(pl)
|
2005-11-04 |
2020-11-16 |
Seqirus UK Limited |
Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
|
PT1951300E
(pt)
*
|
2005-11-04 |
2011-09-05 |
Novartis Vaccines & Diagnostic |
Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
|
GB0524409D0
(en)
*
|
2005-11-30 |
2006-01-11 |
Glaxosmithkline Biolog Sa |
Vaccines
|
GB0524408D0
(en)
*
|
2005-11-30 |
2006-01-11 |
Glaxosmithkline Biolog Sa |
Vaccines
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
AU2006325225B2
(en)
|
2005-12-14 |
2013-07-04 |
Cytos Biotechnology Ag |
Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
NO345368B1
(no)
|
2005-12-22 |
2021-01-04 |
Glaxosmithkline Biologicals Sa |
Streptococcus pneumoniae immunogen sammensetning for anvendelse ved behandling eller forebygging av sykdommer forårsaket av Streptococcus pneumoniae infeksjon ved serotype 19A-stammer.
|
WO2007079190A2
(en)
*
|
2005-12-29 |
2007-07-12 |
Tti Ellebeau, Inc. |
Device and method for enhancing immune response by electrical stimulation
|
FR2896162B1
(fr)
*
|
2006-01-13 |
2008-02-15 |
Sanofi Pasteur Sa |
Emulsion huile dans eau thermoreversible
|
BRPI0710210A2
(pt)
|
2006-03-30 |
2011-05-24 |
Glaxomithkline Biolog S A |
composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
|
EP2382988A1
(de)
|
2006-03-31 |
2011-11-02 |
Novartis AG |
Kombinierte mukosale und parenterale Immunisierung gegen HIV
|
EP2390353A1
(de)
|
2006-06-02 |
2011-11-30 |
GlaxoSmithKline Biologicals S.A. |
Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen CD69
|
WO2007144150A1
(en)
|
2006-06-12 |
2007-12-21 |
Cytos Biotechnology Ag |
Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
|
TW200819462A
(en)
|
2006-07-18 |
2008-05-01 |
Glaxosmithkline Biolog Sa |
Vaccines for malaria
|
GB2453475B
(en)
*
|
2006-07-25 |
2011-01-19 |
Secr Defence |
Live vaccine strain
|
HUE037808T2
(hu)
|
2006-09-26 |
2018-09-28 |
Infectious Disease Res Inst |
Szintetikus adalékanyagot tartalmazó vakcina kompozíció
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
WO2008057529A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Coley Pharmaceutical Group, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
|
WO2008063129A1
(en)
*
|
2006-11-20 |
2008-05-29 |
Duecom |
Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
|
WO2008112125A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Merck & Co., Inc. |
Papillomavirus vaccine compositions
|
US8518903B2
(en)
|
2007-04-19 |
2013-08-27 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of toll-like receptor-9 agonists
|
US20100285041A1
(en)
*
|
2007-05-17 |
2010-11-11 |
Eugen Uhlmann |
Class A Oligonucleotides with Immunostimulatory Potency
|
CN101784282B
(zh)
|
2007-06-26 |
2015-07-08 |
葛兰素史密丝克莱恩生物有限公司 |
包含肺炎链球菌荚膜多糖缀合物的疫苗
|
JP2010536907A
(ja)
|
2007-08-31 |
2010-12-02 |
ニューリミューン セラピューティクス エイジー |
患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
|
EP2034022A1
(de)
*
|
2007-09-10 |
2009-03-11 |
Universite Libre De Bruxelles |
Leukotrien-B4-bindender und löslicher Lipolacin-Rezeptor aus Ixodes ricinus
|
KR101679812B1
(ko)
*
|
2007-09-14 |
2016-11-28 |
사노피 파스테르 바이오로직스, 엘엘씨 |
클로스트리듐 디피실리 톡소이드 a 및 b를 포함하는 약학적 조성물
|
MX2010002965A
(es)
|
2007-09-17 |
2010-09-14 |
Oncomethylome Sciences Sa |
Deteccion mejorada de la expresion de mage-a.
|
AU2008303023B2
(en)
|
2007-09-27 |
2014-01-09 |
Immunovaccine Technologies Inc. |
Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
|
EP2045263A1
(de)
|
2007-10-02 |
2009-04-08 |
Universite Libre De Bruxelles |
Identifizierung und molekulare Charakterisierung von in den Speicheldrüsen von Zecken exprimierten Speichel-Metalloproteasen
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
JP2011506334A
(ja)
|
2007-12-07 |
2011-03-03 |
ノバルティス アーゲー |
免疫応答を誘導するための組成物
|
US10383887B2
(en)
|
2008-02-20 |
2019-08-20 |
New York University |
Preventing and treating amyloid-beta deposition by stimulation of innate immunity
|
EP2265640B1
(de)
|
2008-03-10 |
2015-11-04 |
Children's Hospital & Research Center at Oakland |
Chimere faktor-h-bindende proteine (fhbp), die eine heterologe b-domäne enthalten, und anwendungsverfahren
|
US20110070298A1
(en)
*
|
2008-06-05 |
2011-03-24 |
Immunovaccine Technologies Inc. |
Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
|
AU2012258478B2
(en)
*
|
2008-06-27 |
2013-10-03 |
Zoetis Services Llc |
Novel adjuvant compositions
|
DK3056214T3
(da)
|
2008-06-27 |
2019-05-13 |
Zoetis Services Llc |
Hidtil ukendte adjuvanssammensætninger
|
WO2010036293A1
(en)
*
|
2008-09-24 |
2010-04-01 |
The Johns Hokins University |
Malaria vaccine
|
CN102176907A
(zh)
*
|
2008-10-08 |
2011-09-07 |
免疫解决方案有限公司 |
用于产生粘膜免疫的口服疫苗
|
CN102245198B
(zh)
|
2008-12-09 |
2016-08-17 |
辉瑞疫苗有限责任公司 |
IgE CH3肽疫苗
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
JP5642712B2
(ja)
|
2009-02-10 |
2014-12-17 |
ノバルティス アーゲー |
少ない量のスクアレンを含むインフルエンザワクチン
|
SG173194A1
(en)
*
|
2009-02-17 |
2011-09-29 |
Glaxosmithkline Biolog Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
AU2014200047C1
(en)
*
|
2009-02-17 |
2017-01-19 |
Glaxosmithkline Biologicals S.A. |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
AU2010225125A1
(en)
|
2009-03-17 |
2011-10-20 |
Glaxosmithkline Biologicals S.A. |
Improved detection of gene expression
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
BRPI1011072B1
(pt)
|
2009-06-05 |
2021-09-28 |
Infectious Disease Research Institute |
Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
|
KR20130127547A
(ko)
|
2009-07-30 |
2013-11-22 |
화이자 백신스 엘엘씨 |
항원성 타우 펩타이드 및 이의 용도
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
CA2771863A1
(en)
*
|
2009-08-26 |
2011-03-17 |
Selecta Biosciences, Inc. |
Compositions that induce t cell help
|
SG178447A1
(en)
|
2009-09-03 |
2012-03-29 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
WO2011077309A2
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Vaccines Llc |
Vaccine compositions
|
JP2013522287A
(ja)
*
|
2010-03-18 |
2013-06-13 |
ノバルティス アーゲー |
血清群b髄膜炎菌のためのアジュバント添加ワクチン
|
CN105315351A
(zh)
|
2010-03-30 |
2016-02-10 |
奥克兰儿童医院及研究中心 |
改性的h因子结合蛋白(fhbp)及其使用方法
|
EP3388081A1
(de)
|
2010-05-26 |
2018-10-17 |
Selecta Biosciences, Inc. |
Multivalente synthetische nanoträger-impfstoffe
|
US8895017B2
(en)
|
2010-06-07 |
2014-11-25 |
Pfizer Inc. |
HER-2 peptides and vaccines
|
EP2575868A1
(de)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige-ch3-peptidimpfstoff
|
WO2012038801A1
(en)
|
2010-09-21 |
2012-03-29 |
National Institute Of Immunology |
A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
|
US9072760B2
(en)
|
2010-09-24 |
2015-07-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
|
US10668092B2
(en)
|
2010-09-24 |
2020-06-02 |
The John Hopkins University |
Compositions and methods for treatment of inflammatory disorders
|
WO2012064659A1
(en)
|
2010-11-08 |
2012-05-18 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2012088425A2
(en)
|
2010-12-22 |
2012-06-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
JP2014510721A
(ja)
|
2011-02-15 |
2014-05-01 |
イミューン デザイン コーポレイション |
ベクターワクチンによる免疫原特異的免疫応答を強化するための方法
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
JP6054942B2
(ja)
|
2011-04-08 |
2016-12-27 |
イミューン デザイン コーポレイション |
免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
|
SG10201911993UA
(en)
|
2011-04-22 |
2020-02-27 |
Wyeth Llc |
Compositions relating to a mutant clostridium difficile toxin and methods thereof
|
WO2012156391A1
(en)
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
BR112014002139A2
(pt)
|
2011-07-29 |
2017-02-21 |
Selecta Biosciences Inc |
nanotransportadores sintéticos que geram respostas imunes humorais e de linfócitos t citotóxicos (ctl)
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2850857C
(en)
|
2011-10-06 |
2022-07-26 |
Immunovaccine Technologies Inc. |
Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
|
US9902760B2
(en)
|
2011-11-23 |
2018-02-27 |
Bioven 3 Limited |
Recombinant proteins and their therapeutic uses
|
RS58868B1
(sr)
|
2012-02-07 |
2019-08-30 |
Infectious Disease Res Inst |
Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
|
EP2659906A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2844282B1
(de)
|
2012-05-04 |
2019-06-12 |
Pfizer Inc |
Prostata-assoziierte antigene und immuntherapieschemata auf impfstoffbasis
|
KR102136433B1
(ko)
|
2012-05-16 |
2020-07-22 |
이뮨 디자인 코포레이션 |
Hsv-2 백신
|
US9562066B2
(en)
*
|
2012-09-25 |
2017-02-07 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Oral therapy of necrotizing enterocolitis
|
BR122016023101B1
(pt)
|
2012-10-21 |
2022-03-22 |
Pfizer Inc |
Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
|
WO2014095866A1
(en)
*
|
2012-12-17 |
2014-06-26 |
Eurocine Vaccines Ab |
Intranasal vaccination dosage regimen
|
CA2904506A1
(en)
|
2013-03-15 |
2014-09-18 |
Bioven 3 Limited |
Self-assembling synthetic proteins
|
AU2014237499B2
(en)
*
|
2013-03-15 |
2018-11-15 |
Corium Pharma Solutions, Inc. |
Microstructure array for delivery of active agents
|
US9909114B2
(en)
|
2013-03-28 |
2018-03-06 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
EP3711768A1
(de)
|
2013-04-18 |
2020-09-23 |
Immune Design Corp. |
Gla-monotherapie zur verwendung in der krebsbehandlung
|
EP2996718B1
(de)
|
2013-05-15 |
2020-01-15 |
The Governors of the University of Alberta |
E1e2-hcv-impfstoffe und verfahren zur verwendung
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
KR20190009840A
(ko)
*
|
2013-09-19 |
2019-01-29 |
조에티스 서비시즈 엘엘씨 |
유성 아쥬반트
|
JP6741580B2
(ja)
|
2013-12-31 |
2020-08-19 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
単一バイアルのワクチン製剤
|
EP3607966A1
(de)
|
2014-01-21 |
2020-02-12 |
Pfizer Inc |
Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen und verwendungen davon
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
CA2955015A1
(en)
|
2014-07-15 |
2016-01-21 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
EP4074726A3
(de)
|
2014-07-23 |
2022-11-23 |
Children's Hospital & Research Center at Oakland |
Faktor-h-bindende proteinvarianten und verfahren zur verwendung davon
|
BR112017013891B1
(pt)
|
2015-01-15 |
2024-01-30 |
Pfizer Inc |
Composições imunogênicas para uso em vacinas pneumocócicas
|
HRP20230752T1
(hr)
|
2015-01-16 |
2023-10-27 |
Zoetis Services Llc |
Cjepivo protiv slinavke i šapa
|
CN104857511B
(zh)
*
|
2015-02-13 |
2018-03-30 |
浙江大学 |
含人参皂甙的疫苗稀释剂
|
EP3078381A1
(de)
*
|
2015-04-10 |
2016-10-12 |
Warszawski Uniwersytet Medyczny |
Extrakt von gewöhnlicher rosskastanie oder aescins zur behandlung von alzheimer-krankheit
|
AU2016271857B2
(en)
|
2015-06-03 |
2020-05-28 |
Affiris Ag |
IL-23-P19 vaccines
|
EP3319988A1
(de)
|
2015-07-07 |
2018-05-16 |
Affiris AG |
Impfstoffe zur behandlung und prävention von ige-vermittelten krankheiten
|
CA2936378A1
(en)
|
2015-07-21 |
2017-01-21 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
DK3405212T3
(da)
|
2016-01-19 |
2020-08-24 |
Pfizer |
Cancervacciner
|
CN105770887A
(zh)
*
|
2016-03-04 |
2016-07-20 |
邓招红 |
一种用于hbv疫苗的佐剂及其制备方法
|
CA3020542A1
(en)
|
2016-04-11 |
2017-10-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions for detecting single t cell receptor affinity and sequence
|
US11344619B2
(en)
|
2016-05-16 |
2022-05-31 |
Access To Advanced Health Institute |
Formulation containing TLR agonist and methods of use
|
KR102483033B1
(ko)
|
2016-05-16 |
2022-12-30 |
액세스 투 어드밴스드 헬스 인스티튜트 |
페길화된 리포솜 및 이의 용도
|
MX2021010105A
(es)
|
2016-06-01 |
2022-06-16 |
Infectious Disease Res Inst |
Particulas de nanoalumbre que contienen un agente de dimensionamiento.
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
RU2762723C2
(ru)
|
2017-01-20 |
2021-12-22 |
Пфайзер Инк. |
Иммуногенные композиции для применения в пневмококковых вакцинах
|
EP4083063A3
(de)
|
2017-04-18 |
2023-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Antigenspezifische immuneffektorzellen
|
KR20200028395A
(ko)
|
2017-06-15 |
2020-03-16 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
AU2018304957A1
(en)
|
2017-07-18 |
2020-02-13 |
In3Bio Ltd |
Synthetic proteins and therapeutic uses thereof
|
JP7339942B2
(ja)
|
2017-09-08 |
2023-09-06 |
アクセス ツー アドバンスト ヘルス インスティチュート |
サポニンを含むリポソーム製剤および使用方法
|
US20200254081A1
(en)
|
2017-09-28 |
2020-08-13 |
Pfizer Inc. |
Compositions and methods for eliciting an immune response against clostridium difficile
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
KR20210090618A
(ko)
*
|
2018-09-27 |
2021-07-20 |
제노세아 바이오사이언스, 인코퍼레이티드 |
치료 방법
|
WO2020106621A1
(en)
|
2018-11-19 |
2020-05-28 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
US20220031749A1
(en)
|
2018-11-28 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
BR112021010248A2
(pt)
|
2018-11-29 |
2021-08-17 |
Board Of Regents, The University Of Texas System |
métodos para expansão ex vivo de células naturais killer e uso dos mesmos
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
EP3946444A1
(de)
|
2019-04-01 |
2022-02-09 |
Pfizer Inc. |
Zusammensetzungen und verfahren zur auslösung einer immunreaktion gegen clostridium difficile
|
EP3952906A1
(de)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
|
WO2020232407A1
(en)
*
|
2019-05-16 |
2020-11-19 |
Trustees Of Tufts College |
Peptide antibiotics and methods of use thereof
|
CN114340665A
(zh)
|
2019-05-25 |
2022-04-12 |
传染病研究所 |
用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
|
WO2020260947A1
(en)
|
2019-06-25 |
2020-12-30 |
In3Bio Ltd. |
Stabilized chimeric synthetic proteins and therapeutic uses thereof
|
EP4051696A1
(de)
|
2019-11-01 |
2022-09-07 |
Pfizer Inc. |
Escherichia-zusammensetzungen und verfahren dafür
|
EP4058581A1
(de)
|
2019-11-15 |
2022-09-21 |
Infectious Disease Research Institute |
Rig-i-agonist und adjuvans-formulierung zur tumorbehandlung
|
JP2023506439A
(ja)
*
|
2019-12-13 |
2023-02-16 |
遠大賽威信生命科学(南京)有限公司 |
医薬組成物及びその用途
|
CN111057738A
(zh)
*
|
2020-01-02 |
2020-04-24 |
浙江大学 |
C2c12细胞在疫苗佐剂机制研究中的用途和研究分析方法
|
EP4107173A1
(de)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Verfahren zur expansion tumorinfiltrierender lymphozyten und deren verwendung
|
MX2022010355A
(es)
|
2020-02-21 |
2022-09-21 |
Pfizer |
Purificacion de sacaridos.
|
CA3173729A1
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
FI20215508A1
(en)
|
2020-04-09 |
2021-10-10 |
Niemelae Erik Johan |
Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
|
US20230218735A1
(en)
|
2020-06-19 |
2023-07-13 |
Pfizer Inc. |
Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
|
KR20220002091A
(ko)
*
|
2020-06-30 |
2022-01-06 |
아이진 주식회사 |
양이온성 리포좀을 포함하는 사포닌의 용혈 억제용 조성물
|
CA3173951A1
(en)
|
2020-09-04 |
2022-03-10 |
Emily VOIGT |
Genetically-adjuvanted rna vaccines
|
CA3174411A1
(en)
|
2020-09-04 |
2022-03-10 |
Ryan M. Kramer |
Co-lyophilized rna and nanostructured lipid carrier
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
EP4240410A1
(de)
|
2020-11-04 |
2023-09-13 |
Pfizer Inc. |
Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
AU2021377699A1
(en)
|
2020-11-13 |
2023-06-15 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
EP4251645A1
(de)
|
2020-11-25 |
2023-10-04 |
Catamaran Bio, Inc. |
Mit signalmodulatoren manipulierte zelluläre therapeutika und verfahren zur verwendung davon
|
CN117120087A
(zh)
|
2020-12-23 |
2023-11-24 |
高级健康研究所 |
茄尼醇疫苗助剂及其制备方法
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
MX2023009728A
(es)
|
2021-02-19 |
2023-08-30 |
Sanofi Pasteur Inc |
Vacuna recombinante meningococica b.
|
AU2022281543A1
(en)
|
2021-05-28 |
2023-11-23 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
CN113797329A
(zh)
*
|
2021-10-19 |
2021-12-17 |
启锰生物科技(江苏)有限公司 |
一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023089556A1
(en)
|
2021-11-22 |
2023-05-25 |
Pfizer Inc. |
Reducing risk of antigen mimicry in immunogenic medicaments
|
CN116212012A
(zh)
*
|
2021-12-02 |
2023-06-06 |
上海泽润生物科技有限公司 |
复合佐剂以及包含它的疫苗制剂
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|